Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Zhongzhi Pharmaceutical Holdings Limited ( (HK:3737) ) is now available.
Zhongzhi Pharmaceutical Holdings reported that all resolutions at its 2026 annual general meeting on 13 May 2026 were approved by shareholders via poll, covering the adoption of the 2025 audited accounts, re-election of directors and authorization of directors’ remuneration. Shareholders also backed the re-appointment of Ernst & Young as auditor and granted the board general mandates to repurchase up to 10% of issued shares and to issue up to 20% new shares, reinforcing management’s financial flexibility and capital management options without recorded opposition or abstentions.
More about Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited is a Cayman Islands-incorporated company listed in Hong Kong, operating in the pharmaceutical sector. The group focuses on the development, production and sale of pharmaceutical products, serving healthcare markets primarily accessed through its Hong Kong listing under stock code 3737.
Average Trading Volume: 488,381
Technical Sentiment Signal: Buy
Current Market Cap: HK$694.5M
For detailed information about 3737 stock, go to TipRanks’ Stock Analysis page.